Methyl salicylate

Methyl Salicylate: Recent Market Intelligence Report

I. Price Dynamics
- Latest Quotations: As of June 23, 2026, methyl salicylate market quotations exhibit regional variation. In Hubei Province, the mainstream quotation for 99% purity grade stands at RMB 19,400–19,500 per metric ton; in Zibo, Shandong Province, the premium-grade quotation is RMB 19,400 per metric ton; and in Jiangsu Province, the quotation for 99% purity grade is RMB 15,300 per metric ton.
- Price Volatility: Recent price fluctuations have been modest. Quotations in Hubei Province remained unchanged compared to June 15, while Jiangsu Province saw no significant adjustment from prior levels—indicating a broadly balanced supply-demand relationship.

II. Supply-Demand Landscape
- Supply Side:
- Capacity Utilization: By end-2025, China’s total designed annual production capacity for methyl salicylate reached 63,000 metric tons, with an apparent domestic consumption volume of approximately 42,000 metric tons—yielding a capacity utilization rate of ~66.7%. This falls below the healthy operational threshold (75%–85%), signaling a risk of temporary overcapacity.
- Market Concentration: Four leading enterprises—Jiangsu Huachang Chemical Co., Ltd., Zhejiang Xinan Chemical Industrial Group Co., Ltd., Shandong Xinhua Pharmaceutical Co., Ltd., and Changshu Hongwen Chemical Co., Ltd.—collectively account for 62.4% of the domestic market share. The CR4 (four-firm concentration ratio) has risen steadily year-on-year, reflecting accelerated exit of small- and medium-sized producers.
- Demand Side:
- Pharmaceuticals: In 2025, pharmaceutical applications accounted for 44.2% of total demand, primarily as a key intermediate in synthesizing antipyretic and analgesic active pharmaceutical ingredients (APIs). Policy support from China’s National Medical Products Administration (NMPA) promoting novel gel-based formulations is expected to drive pharmaceutical-sector demand growth by 9.5% in 2026.
- Fragrance & Cosmetics: This segment represented 31.5% of demand in 2025, mainly used in mint- and wintergreen-type fragrance bases. The China Association of Fragrance, Flavor and Cosmetic Industries forecasts domestic procurement of wintergreen oil-type fragrance bases to reach 8,600 metric tons in 2026, implying corresponding methyl salicylate demand of ~4,100 metric tons—a 7.9% year-on-year increase.
- Export Markets: In 2025, export volume totaled 12,800 metric tons, up 5.3% year-on-year, with primary destinations including India, Brazil, and ASEAN countries. Under the Regional Comprehensive Economic Partnership (RCEP), tariff rates on methyl salicylate exports to ASEAN nations have been reduced to zero, supporting an anticipated export growth rate of 6.8% in 2026.

III. Cost & Profitability
- Raw Material Costs: Methyl salicylate production relies on upstream feedstocks such as salicylic acid, phenol, and methanol. Recently, the pricing center for these raw materials has shifted downward; combined with broader adoption of continuous-flow microreactor technology, the industry’s weighted-average production cost declined by 4.7% year-on-year.
- Profitability: In 2025, the sector’s average gross margin stood at 28.3%, exceeding the overall average for fine chemical intermediates (24.7%). This outperformance stems primarily from an increased share of high-value pharmaceutical-grade products (37.2% of output), which command an average selling price 62.4% higher than industrial-grade equivalents.

IV. Policy & Environmental Regulations
- Policy Support: The Chinese government has designated methyl salicylate as a key monitored substance under its “Essential Shortage-Prone Basic APIs” program, encouraging technological upgrades and capacity expansion among leading firms. For instance, North China Pharmaceutical Group completed a smart production line upgrade (300 metric tons/year), and China Resources Double-Crane Pharmaceuticals initiated Phase II expansion at its Cangzhou base (adding 200 metric tons/year).
- Environmental Pressure: Under China’s “Dual Carbon” (carbon peak & carbon neutrality) strategy and tightening environmental regulations, enterprises face mounting compliance costs. Greenbloom Chemical Co., Ltd. implemented a wastewater cascade reuse process, reducing specific energy consumption per unit of product by 18.4%—highlighting continuous-flow microreactor technology and other green synthesis methods as critical competitive differentiators.

Analysis & Outlook
1. Short-Term Price Stability: Given the current equilibrium in supply and demand, methyl salicylate prices lack strong catalysts for large-scale fluctuation; narrow-range, regionally differentiated price oscillation is expected in the near term.
2. Structural Opportunities Emerging:
- Pharmaceutical-Grade Demand: Policy-driven development of novel dosage forms creates sustained growth in high-end pharmaceutical-grade demand—firms with CGMP-certified production lines stand to benefit significantly.
- Export Growth: RCEP tariff advantages and expanding contract manufacturing capacity across Southeast Asia are positioning exports as a vital growth engine.
3. Accelerated Capacity Rationalization: Smaller producers face mounting pressure from rising environmental compliance costs and technical barriers, accelerating their market exit—and further elevating industry concentration.

Projections
1. Market Size: The compound annual growth rate (CAGR) for the methyl salicylate industry is projected to stabilize between 6.8% and 7.2% during 2026–2028, with the market size exceeding RMB 1.55 billion by 2028.
2. Price Divergence: Prices for pharmaceutical-grade products—supported by high technical barriers and robust demand growth—are expected to remain resilient; conversely, industrial-grade products will face continued pricing pressure due to overcapacity.
3. Technology-Led Transformation: Widespread adoption of continuous-flow microreactor systems, green catalytic processes, and other innovative technologies will propel the industry toward high-quality, low-carbon development—firms with advanced technical capabilities and R&D reserves will gain first-mover advantage.